Camurus and Eli Lilly have entered a global collaboration and license agreement granting Lilly exclusive rights to research, develop, manufacture, and commercialise long‑acting incretin therapies based on Camurus’s FluidCrystal delivery technology. The agreement encompasses up to four Lilly‑owned drug compounds targeting cardiometabolic conditions, including dual GIP/GLP‑1 receptor agonists, triple GIP/glucagon/GLP‑1 agonists, with an option to include amylin receptor agonists.

Under the terms, Camurus stands to receive up to $290 million in upfront, development, and regulatory milestone payments, plus an additional $580 million in sales‑based milestones, along with tiered mid‑single‑digit royalties on global product sales. Camurus emphasised that this partnership allows Lilly to utilise their FluidCrystal platform in expanding metabolic disease areas, while Camurus continues to focus its own commercial efforts on treatments for central nervous system and rare diseases.